The Lilly Biotechnology Middle in San Diego, California, on March 1, 2023.
Mike Blake | Reuters
Eli Lilly on Thursday reported blended effects for the fourth quarter as gross sales of its blockbuster weight reduction and diabetes medicine soared but it surely noticed decrease learned costs.
The figures had been in keeping with the initial effects Eli Lilly shared in January, which disillusioned traders. Eli Lilly had slashed its 2024 income steering, because it stated call for for its weight reduction and diabetes medicine would now not meet its imposing expectancies.
The corporate’s income crowned Wall Boulevard estimates, however gross sales fell simply snip.
Right here’s what Eli Lilly reported for the duration when compared with what Wall Boulevard was once anticipating, in line with a survey of analysts by way of LSEG:
- Profits in line with percentage: $5.32 adjusted vs. $4.95 anticipated
- Earnings: $13.53 billion vs. $13.57 billion anticipated
This tale is creating. Please test again for updates.
